$XBI $128.58 -0.45%
Covid Updates
$SRNE -3.0% Sorrento Exercises Exclusive Option Agreement With Texas A&M University for MPRO Inhibitors Against Sars-Cov-2 and all Variants of Concern. source
$SRNE -3.0% Sorrento Reports Promising Results With mRNA Vaccine For COVID-19 Delivered With The MuVaxx Lymphatic Drug Delivery Device. source
$INO+3.1% INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800. source
$BNTX -0.3% Pfizer and BioNTech Announce Collaboration with Brazil’s Eurofarma to Manufacture COVID-19 Vaccine Doses for Latin America. source
$RDHL +1.5% RedHill Biopharma's Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant. source
Pipeline Updates
$BOLT +0.6% Bolt Biotherapeutics and Innovent Biologics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs. source
$INCY -0.8% Incyte and MorphoSys Announce the European Commission Approval of Minjuvi® (tafasitamab) in Combination With Lenalidomide for the Treatment of Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. source
$DNLI-4.2% Denali Therapeutics Announces Publication in Cell on New Approach to Treat FTD-GRN. source
$AGEN +4.1% Balstilimab Monotherapy Data Published in Gynecologic Oncology. source
$ZGNX -1.5% Zogenix Receives Orphan Drug Designation for FINTEPLA® (Fenfluramine) in Japan. source
$MRNS-0.6% European Medicines Agency Grants Marinus Pharmaceuticals Accelerated Assessment of Ganaxolone for Treatment of CDKL5 Deficiency Disorder. source
$AVXL -2.6% Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Autism). source
$IRWD-0.3% Ironwood Pharmaceuticals Announces FDA Approval of Revised LINZESS® (linaclotide) Label. source
$LABP -0.2% Landos Biopharma Announces Research Collaboration into the NLRX1 Pathway in Multiple Sclerosis with Johns Hopkins University School of Medicine. source
$PLXP -0.4% PLx Pharma Inc.’s VAZALORE™ Now on Shelves; National Media Campaign Launches Today. source
$AZN +0.3% Forxiga approved in Japan for the treatment of chronic kidney disease in patients with and without type-2 diabetes. source
$AZN +0.3% ALXN1840 FoCus Phase III trial in Wilson disease met primary endpoint demonstrating improvement in copper mobilisation from tissues. source
$HCM -2.3% HUTCHMED Initiates a Phase Ib/II Trial of Fruquintinib in Combination with Tislelizumab in Advanced Triple Negative Breast Cancer or Advanced Endometrial Cancer. source
$SAVA -12.4% On 8/25 Cassava Sciences Responds to Allegations. source
$BYSI +18.7% BeyondSpring Announces Exclusive Commercialization and Co-development Agreement with Jiangsu Hengrui Pharmaceuticals for Plinabulin in Greater China. source
$ASND +21.1% On 8/25 Ascendis Pharma A/S Reports Second Quarter 2021 Financial Results. source
Market update
$HTBX +0.5% Heat Biologics Unveils Skunkworx Bio, New Drug Discovery Subsidiary. source
$PLX +3.4% Protalix BioTherapeutics Announces Closing of Private Note Exchange. source
Posted by FS
Comments